Search
Dacarbazine
go.drugbank.com/drugs/DB00851ApprovedInvestigationalAn antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564).
Categories: Antineoplastic and Immunomodulating AgentsDesirudin
go.drugbank.com/drugs/DB11095ApprovedWithdrawnCommon side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing. … Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52.
Categories: Blood and Blood Forming Organs, Amino Acids, Peptides, and ProteinsLandiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigational[A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November … [A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity
Gefapixant
go.drugbank.com/drugs/DB15097ApprovedIt has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.
Categories: Cough and Cold PreparationsRilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigational[L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
Actoxumab
go.drugbank.com/drugs/DB16376InvestigationalActoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
Categories: Amino Acids, Peptides, and ProteinsAvasopasem manganese
go.drugbank.com/drugs/DB16354Investigational[L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19.
Abarelix
go.drugbank.com/drugs/DB00106ApprovedWithdrawnIt is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Categories: Amino Acids, Peptides, and Proteins, Hormone Antagonists and Related AgentsDofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationaland flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. … Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.
Categories: Antineoplastic and Immunomodulating Agents